![](https://canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBYmc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--fc8c9736275a59b5f0bcf52c0566e1f125008779/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/Iterum-Logo-01-colored-updated01.fw_.png)
Iterum Therapeutics
Iterum Therapeutics is developing an IV and oral gram negative antibacterial.
Website
www.iterumtx.comPartner
Brent AhrensInvestment
Series A
Iterum Therapeutics is developing an IV and oral gram negative antibacterial.
Series A